Skip to main content

Head and Neck, Squamous Cell Carcinoma, Oral Mucositis (IDR-OM-02)

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and

Overview

Overview

To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer.

Key Inclusion Criteria

Key Inclusion Criteria

For a patient to be eligible for participation in this study, all of the following criteria must apply.

  • Biopsy-proven squamous cell carcinoma of the oral cavity or oropharynx without distant organ metastases
  • Scheduled to receive cisplatin chemotherapy of 80-100 mg/m²
  • Scheduled to receive a continuous course of fractionated, conventional external beam with a cumulative radiation dose between 55 and 72 Gy at each site
Key Exclusion Criteria

Key Exclusion Criteria

A patient will not be eligible for participation in this study if any of the following criteria apply.

  • Current mucositis
  • Current, clinically significant, active infection that in the opinion of the Investigator would make them an unfit participant in the trial
  • Planned to receive Erbitux™ (Cetuximab) or similar targeted therapy between Baseline and 6 weeks post-RT
  • Prior radiation to the head and neck
  • Chemotherapy treatment within the previous 12 months
  • Tumors of the lips, sinuses, salivary glands, nasopharynx, hypopharynx, or larynx
  • Evidence of significant renal, hepatic, hematologic, or immunologic disease determined by any one of the following: Estimated creatinine clearance <30 mL/min; ALT or AST level greater than 10-fold the upper limit of normal or total bilirubin greater than 3-fold the upper limit of normal; Manifestations of end-stage liver disease, such as ascites or hepatic encephalopathy; Thrombocytopenia; or CD4+ T cell count below 200 cells per μL
  • Evidence of immediate life-threatening disease or a life expectancy of less than 3 months
  • Women who are pregnant or breastfeeding
  • Participation in any study involving administration of an investigational agent within 30 days of randomization into this study
Learn More

Learn More

To learn more, visit ClinicalTrials.Gov

Study Type

Phase III

Principal Investigator(s)

Amarinthia Curtis, MD

Sponsor(s)

Soligenix

Contact Us

Contact Us

To participate in this study, please contact Luann Lester at
864-560-1045
Related Providers